Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite black box warning for anaphylaxis and infusion reactions, label and risk plan are seen as "benign" by analysts.
You may also be interested in...
Private Equity-Backed Crealta Makes Its First Move With Savient Deal
A startup called Crealta Pharmaceuticals will acquire most of Savient’s assets, including the marketed gout drug Krystexxa, for $120.4 million following a bankruptcy court auction.
AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.
Savient's New CEO Johnson Tasked With Turning Krystexxa Into A Commercial Success
Eli Lilly's oncology head John Johnson has been named to the top post at Savient Pharmaceuticals as the company tries to rebound from a failed sales attempt.